AN01
Chronic Obstructive Pulmonary Disease (COPD)
Key Facts
About AirNexis Therapeutics
AirNexis Therapeutics is a well-funded, emerging biopharmaceutical company that launched with a substantial $200 million Series A financing round. The company is singularly focused on developing AN01, a first-in-class dual phosphodiesterase 3 and 4 (PDE3/4) inhibitor, for the treatment of COPD, a prevalent and debilitating respiratory disease. With its lead program already in Phase 2 clinical trials, AirNexis is positioned to rapidly advance a potentially differentiated therapeutic that aims to combine bronchodilation and anti-inflammatory effects in a single molecule. The company operates as a private, pre-revenue entity with a concentrated pipeline and a clear path to generating pivotal clinical data.
View full company profileTherapeutic Areas
Other Chronic Obstructive Pulmonary Disease (COPD) Drugs
| Drug | Company | Phase |
|---|---|---|
| PUR0200 | Pulmatrix | Preclinical |
| Dupixent (dupilumab) | Regeneron | Phase 3 |
| REGEND001 | Regend | Phase 1 |
| COPD Trial | Well Pharma Medical Research | Not Specified |
| COPD Diagnostic/Prognostic Test | Oxford Cancer Analytics | Pre-clinical |
| SMS Cell Therapy | SMSbiotech | Phase 1b |
| dNerva Lung Denervation System / Targeted Lung Denervation (TLD) | Nuvaira | Phase 3 |
| LBP for COPD | Alveolus Bio | Preclinical |
| AstraZeneca Collaboration Programs | Ethris | Discovery/Pre-clinical |
| COPD Phenotyping & Progression Biomarkers | Thirona | Commercial/Validation |
| TEZSPIRE (tezepelumab) | Amgen | Phase 3 |
| Verekitug (UPB-101) | Upstream Bio | Phase 2 |